Successful Eradication of Relapsed Primary Effusion Lymphoma with High-Dose Chemotherapy and Autologous Stem Cell Transplantation in a Patient Seronegative for Human Immunodeficiency Virus
- 66 Downloads
Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonim-munosuppressed patients. Patients present with lymphomatous effusions in serous cavities—pleura, pericardium, or peritoneum–without any identifiable tumor mass. PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts. A standard treatment for PEL has not yet been identified. We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.
Key wordsPrimary effusion lymphoma Human herpesvirus 8 High-dose chemotherapy
Unable to display preview. Download preview PDF.
- 13.Cesarman E, Moore PS, Rao PH, Inghirami G, Knowles DM, Chang Y. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi’s sarcoma-associated her-pesvirus-like (KSHV) DNA sequences. Blood. 1995;86:2708–2714.PubMedGoogle Scholar
- 14.Banks PM, Warnke RA. Primary effusion lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues.Lyon, France: IARC Press;2001:179–180.Google Scholar